



In vivo evaluation of a hybrid nanoparticle for molecular imaging of amyloid aggregation

E. Ong, F. Vadcard, M. Verdurand, H. Rositi, F. Peyrin, Y. Berthezene, N. Nighoghossian, F. Lerouge, S. Parola, L. Zimmer, et al.

► To cite this version:

E. Ong, F. Vadcard, M. Verdurand, H. Rositi, F. Peyrin, et al.. In vivo evaluation of a hybrid nanoparticle for molecular imaging of amyloid aggregation. 10th annual meeting of the European Society for Molecular Imaging (ESMI) - European Molecular Imaging Meeting (EMIM), Mar 2015, Tübingen, Germany. hal-01207666

HAL Id: hal-01207666

<https://hal.science/hal-01207666>

Submitted on 1 Oct 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Category : « Imaging Probes, Chemistry & Reporter Genes »
Subcategory : « New concepts for multimodality imaging and reporter probes »

Keywords

amyloid-beta; luminescent conjugated oligothiophenes; magnetic resonance imaging

**In vivo evaluation of a hybrid nanoparticle
for molecular imaging of amyloid aggregation**

Elodie ONG¹, Félix VADCARD², Mathieu VERDURAND³, Hugo ROSITI¹, Françoise PEYRIN¹, Yves BERTHEZENE¹, Norbert NIGHOGHOSSIAN¹, Frédéric LEROUGE², Stéphane PAROLA², Luc ZIMMER³, Marlène WIART¹, Fabien CHAUVEAU³

¹*Univ. Lyon, Medical Imaging Research Center (CREATIS);
CNRS UMR5220; INSERM U1044; INSA-Lyon, Univ. Lyon 1, 69003 Lyon, France*

²*Univ. Lyon, Laboratory of Chemistry;
CNRS UMR5182; ENS Lyon, Univ. Lyon 1, 69003 Lyon, France*

³*Univ. Lyon, Lyon Neuroscience Research Center (CRNL);
CNRS UMR5292; INSERM U1028, Univ. Lyon 1, 69003 Lyon, France*

Introduction

Amyloid- β (A β) fibrillization is described as a central event in the pathogenesis of Alzheimer's disease (AD). Amyloid imaging is expected to play a pivotal role in early and differential diagnosis of dementias, and in the evaluation of anti-A β treatments. Luminescent conjugated oligothiophenes (LCO) have been proposed as optical biomarkers of protein fibrillation [1]. In this paper, we evaluated a fluorescent magnetic hybrid nanoprobe (HNP5011), based on gadolinium fluoride nanoparticles functionalized with luminescent conjugated polythiophenes moieties (Fig. 1). The aim of this study was to investigate its potential for molecular imaging in a rat model bearing intracerebral pre-aggregated A β peptides.

Methods

Recombinant human A β ₁₋₄₂ peptides were agitated at 200 μ M and 37°C. Resulting fibrils were characterized by transmission electron microscopy (TEM) and spectrofluorometry with thioflavine T (ThT). Rats were stereotactically injected with 5 μ l of fibrils on one hippocampus and with PBS on the contralateral side. Blood brain barrier (BBB) integrity was evaluated with magnetic resonance imaging (MRI) after gadolinium injection and with histology after Bleu Evans injection. Macrophage recruitment was highlighted on in vivo MRI and ex vivo Synchrotron Radiation X-ray phase contrast CT (SR-PCT) after ultrasmall superparamagnetic iron oxide injection. The capacity of HNP5011 to detect amyloid fibrils was investigated after stereotaxic (140 μ M, 2.5 μ l) or intravenous (14mM, 75 μ mol Gd/kg) injection of the nanoparticles. Brain sections were used for fluorescence microscopy.

Results

Pre-aggregated A β peptide injection caused transient BBB disruption and macrophage recruitment as well as few complications such as petechial hemorrhage and inflammatory oedema around the injection site. HNP5011 was visible on MRI and SR-PCT after stereotaxic injection (Fig. 2) but not visible after intravenous injection. Post-mortem fluorescence on brain tissue without MRI detection could also be explained by in vivo dissociation of HNP5011.

Conclusion

This preliminary evaluation highlighted the need to bring the HNP5011 solution at a higher concentration to reach MRI detection threshold after intravenous injection. Biostability of the nanoparticle deserves further studies.

References

1. Aslund, et al. ACS Chem. Biol. **2009** ;4, 673–684.

Acknowledgements

M. Verdurand is sponsored by Fondation Plan Alzheimer. This work was performed within the framework of the LABEX PRIMES (ANR-11-LABX-0063) of Univ. Lyon.

Figures




Figure 1. Hybrid nanoparticle 5011.




Figure 2. Back-to-back MRI and SR-PCT detection of intra-cerebral hybrid nanoparticle 5011 injected in right (red) and left (blue) hippocampi after stereotaxic injection of pre-aggregated amyloid fibrils (in left hippocampus only).